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Background: In cystic fibrosis (CF) patients, the upper airways display the same ion channel defect as evident in
the lungs, resulting in chronic inflammation and infection. Recognition of the sinonasal area as a site of first and
persistent infection with pathogens, such as Pseudomonas aeruginosa, reinforces the “one-airway” hypothesis.
Therefore, we assessed the effect of systemic antibiotics against pulmonary pathogens on sinonasal inflammation.
Methods: Nasal lavage fluid (NLF) from 17 CF patients was longitudinally collected prior to and during elective
intravenous (i.v.) antibiotic treatment to reduce pathogen burden and resulting inflammation (median treatment
time at time of analysis: 6 days). Samples were assessed microbiologically and cytologically. Cytokine and
chemokine expression was measured by Cytometric Bead Array and ELISA (interleukin (IL)-1β, IL-6, IL-8, MPO, MMP9,
RANTES and NE). Findings were compared with inflammatory markers from NLF obtained from 52 healthy controls.
Results: Initially, the total cell count of the NLF was significantly higher in CF patients than in controls. However
after i.v. antibiotic treatment it decreased to a normal level. Compared with controls, detection frequencies and
absolute concentrations of MPO, IL-8, IL-6 and IL-1β were also significantly higher in CF patients. The detection
frequency of TNF was also higher. Furthermore, during i.v. therapy sinonasal concentrations of IL-6 decreased
significantly (P = 0.0059), while RANTES and MMP9 levels decreased 10-fold and two-fold, respectively. PMN-Elastase,
assessed for the first time in NFL, did not change during therapy.
Conclusions: Analysis of NLF inflammatory markers revealed considerable differences between controls and CF
patients, with significant changes during systemic i.v. AB treatment within just 6 days. Thus, our data support
further investigation into the collection of samples from the epithelial surface of the upper airways by nasal lavage
as a potential diagnostic and research tool.
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Cystic fibrosis (CF) is the most common autosomal reces-
sive disorder in the Caucasian population and is caused by
mutations in the Cystic Fibrosis Transmembrane Con-
ductance Regulator (CFTR) gene (chromosomal position
7q31.2), leading to altered chloride ion exchange and
hyperviscous mucus in the affected organs. Patients also
suffer from recurrent infections of the respiratory tract
and chronic inflammation, which leads to tissue remodel-
ling and finally to premature death caused by respiratory
insufficiency [1]. The causative CFTR defect also affects
sinonasal mucosa, so that almost 100% of CF patients re-
veal a pathological sinonasal computer tomography [2]. In
addition to impairing the patient’s quality of life, the in-
volvement of the upper airways (UAW) in CF has the po-
tential to aggravate the overall course of disease. Most
importantly, sinonasal involvement in CF facilitates de
novo and persistent airway colonisation with pathogens
including Pseudomonas (P.) aeruginosa [3,4], which is the
major cause of morbidity and mortality. Thus, cross-
colonisation between the airway levels is evident as P.
aeruginosa strains in sputum and UAW specimens in pa-
tients who harbour the pathogen in both airway levels are
genetically identical [4-6]. Additionally, the paranasal si-
nuses have been identified both as a site for the diversifi-
cation of P. aeruginosa before spreading into the lower
airways [7] and as a site of persistence in CF patients who
underwent lung transplantation, whereupon these clones
colonise the transplanted lungs that were primarily free
from P. aeruginosa [8]. It was shown that sinus surgery to-
gether with an intensive antibiotic follow-up treatment, as
well as conservative methods such as sinonasal inhalation
using vibrating aerosols, can eradicate P. aeruginosa from
the upper airways and so decrease pulmonary infection
events [3,9]. Therefore, it is very important to recognize
the upper and lower airways as a “one-airway system”
and not neglect the upper airways in the routine care of
CF patients [10].
Nasal lavage (NL), which is frequently used in the field
of allergies, e.g. for monitoring of provocation effects
[11], is the most sensitive method for non-invasive as-
sessment of pathogen colonisation of the UAWs [4].
Polymorphonuclear leukocytes (PMN) are major players
in the first line of defence against pathogens. Most pro-
teases and cytokines important for host defence and in-
flammation are released by neutrophil cells. Pulmonary
secretions from CF patients obtained by bronchoalveo-
lar lavage (BAL) revealed elevated levels of interleukin
(IL)-1β, IL-6 and TNF, especially in patients infected
with P. aeruginosa [12,13]. Moreover, recently Paats et al.
reported significantly elevated IL-6 concentrations in the
NL of CF patients during acute exacerbations, compared
with controls 3 months later. Systemic IL-6 levels corre-
lated significantly to several clinical parameters in bothstages of disease. In our previous study assessing the NL
of CF patients [14], IL-1β and IL-6 were detected more
frequently in CF compared with healthy controls. In con-
trast, TNF that had been elevated in the BAL of CF pa-
tients was not detectable in the NL-fluid (NLF) of CF and
healthy controls [14]. However, especially for IL-1β, IL-6
and TNF, differences in cytokine expression between
upper and lower airways and peripheral blood were ob-
served, suggesting a compartmentalised local inflamma-
tory response [15,16]. IL-8 encourages neutrophils to
leave the circulation and migrate into the tissue. In the
NLF of CF patients, IL-8 was detected more frequently
than in healthy controls [14]. An increase of PMNs and
IL-8 in the upper airways of CF patients has also been re-
ported [17]. IL-8 mRNA expression was increased in CF
patients [18], and IL-8 levels in UAW and in the lower air-
ways (LAW) showed a significant correlation [19].
Myeloperoxidase (MPO) is produced by stimulated neu-
trophils and catalyses the production of various oxidants
[20,21]. Elevated MPO is an established marker for neutro-
phil activity as it is released in oxidative bursts. In the re-
cent work by Beiersdorf et al. [14], MPO was elevated in
the NL of CF patients compared with healthy controls.
Matrix metalloproteinase 9 (MMP9), also produced by neu-
trophils, is involved in the breakdown of extracellular
matrix proteins such as elastin or collagen [22]. MMPs are
physiologically cleaved by tissue inhibitors of metallopro-
teinases (TIMPs) and are involved in physiological pro-
cesses including tissue remodelling, but also in pathological
processes when their balance is disturbed. In the literature,
the role of the serine protease neutrophil elastase (NE),
which is released on stimulation with TNF or IL-8 [23], has
been intensively studied in the lower airways of CF patients,
but little is known of its relevance in the upper airways.
Normally, NE plays an important role in the processing
and release of cytokines (e.g. IL-6 [24]), modulation of
immune cell activity and mucus secretion [25]. It is also im-
portant in the defence against gram negative bacteria in-
cluding P. aeruginosa by cleaving bacterial cell surface
structures, such as flagella. In the CF lung, NE is over-
expressed leading to dysfunction of the innate and adaptive
immune systems. RANTES/CCL5 (regulated on activation,
normal T cell expressed and secreted) is a chemoattractant
that recruits and activates eosinophils and this was shown
to be elevated in nasal polyps of CF patients [26].
Non-invasively collected NL from the patient’s UAW
epithelial lining fluid can open the field to monitor air-
way colonisation, host defence and inflammation, which
has rarely been considered in the recent literature. In par-
ticular, monitoring inflammatory mediators in NLF during
interventions as a non-invasive outcome parameter re-
quires further investigation. The aim of the present study
is to assess changes in leukocyte populations and expres-
sion of IL-1β, IL-6, IL-8, TNF, RANTES, MPO, MMP9
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systemic antibiotic (AB) treatment to establish a better
understanding of inflammation and immune defence
mechanisms. The findings were also compared with in-
flammatory markers in NLF from a healthy control group.
Methods
Study population
Paediatric and adult patients, diagnosed with CF by two
sweat tests and/or detection of two causative CFTR-muta-
tions, who electively received systemic i.v. AB treatment,
were prospectively included in the study at the CF Centre,
Jena University Hospital, between August and December
2010. All patients were chronically colonised with high-
risk pathogens. They were treated electively with i.v. AB,
according to a standard used in many European CF
Centres [27] to reduce pathogen burden, inflammatory re-
sponses and pulmonary destruction. The inclusion criteria
were the ability to perform NL (see below) and be CF pa-
tients receiving elective i.v. AB treatment as part of their
routine care. The exclusion criteria were perforation of
tympanic membranes and a previously initiated systemic
AB therapy within the previous 2 weeks. Only azithromy-
cin (AZM) therapy was allowed and documented.
Sinonasal samples were taken directly before and dur-
ing/after i.v. therapy. Chronic rhinosinusitis (CRS) in CF
patients was diagnosed according to the European position
paper on rhinosinusitis and nasal polyps 2012 (EPOS) [28].
Clinical data (e.g. lung function, systemic inflammation)
were assessed only before, and not after, AB treatment as
patients completed treatment at home.
The 52 healthy controls were recruited as described
previously [14].
Ethics statement
All patients (or parents of minors) gave their written in-
formed consent. The study was approved by the Ethics
Committee of the Jena University Hospital.
Nasal lavage (NL)
Sampling
NL was performed as previously described [4,29] using
10 mL of sterile isotonic saline (NaCl) for each nostril.
Backflow was rinsed into a sterile plastic cup supported
by the patient breathing out lightly.
NL processing
Recovered volumes were measured before aliquoting. An
aliquot was directly sent for microbiological analysis (see
below). Another aliquot was used for cytological analysis
after stabilising cells in 10% foetal calf serum (FCS, Bio-
chrom, Berlin, Germany). The lavage sample was centri-
fuged (160×g, 10 min, RT), supernatant discarded and the
pellet resuspended in 1 mL 0.9% NaCl supplemented with10% FCS. The remaining volume of NLF was divided; one
part was stored without centrifugation (natively) at −80°C,
the other one was centrifuged (160×g, 10 min, RT), and
supernatant was frozen at −80°C within 45 minutes of
sampling. A protease inhibitor cocktail (Protease Inhibitor
Mix G, Serva, Germany) was added to each aliquot prior
to freezing. The protein concentration was measured in
single assays at a wavelength of 280 nm using a NanoDrop
ND 1000 spectrophotometer (Thermo Fisher Scientific
Inc., Waltham, MA, USA).
Cytological analysis
Analysis of the total cell count and the automated differ-
entiation of cells was performed using a XE-5000 haemo-
cytometer (Sysmex, Norderstedt, Germany) in Body Fluid
Modus. For cytological differentiation, cytospin prepara-
tions of 100 cells were prepared.
Microbiological analysis
Microbiological analyses were performed according to
European standards [30]. Permanent and intermittent
colonisation was determined using the criteria published
by Lee et al. [31], where chronic colonisation is when
more than 50% of cultures within the preceding year are
positive and intermittent colonisation is if less than 50%
of cultures are positive for a given pathogen.
Immunological analysis
Cytometric bead array and FACS analysis
Analysis of MMP9, MPO, RANTES, IL-1β, IL-6, IL-8
and TNF was carried out using a Cytometric Bead Array
(FlowCytomix, eBioscience, San Diego, CA, USA) followed
by flow cytometry (FACS Calibur, BD, Franklin Lakes, NJ,
USA) as described elsewhere [14]. The results were evalu-
ated using FlowCytomix Pro 2.3 software (eBioscience,
Frankfurt, Germany). Bead array experiments were done
in single assays. Table 1 provides details of the detection
limits.
ELISA
NL PMN-Elastase (NE) concentrations were determined in
duplicates of 100 μl NLF using the PMN-Elastase ELISA
according to the manufacturer’s instructions (eBioscience,
No. BMS269). An automated washer (SLT Typ Columbus,
Labtechnologies, Austria) was used to wash plates and a
FluoStar Galaxy spectrometer (BMG Labtechnologies,
Offenburg, Germany) was used for detection.
Body Mass Index (BMI)
Our study population includes children and adults. For
children and adolescents, the WHO classification of under-
weight, normal and overweight are not suitable. Moreover,
for people with chronic diseases leading to malnutrition
and delayed growth, the usage of BMI can be problematic.
Table 1 Inflammation markers in controls and CF patients before and during AB treatment
Analyte DL














MMP9 (ng/mL) 0.095 n.m. 100.0 100.0 --- n.m. 11.4 5.5 n.m. 2.02-122.2 1.8-25.2 0.0523‡
MPO (ng/mL) 0.2 71.2 100.0 100.0 0.0008◊† 33.4 215.3 171.9 0.1-182.7 54.36-531.1 21.4-533.4 0.0008◊†
0.7404‡
IL-8 (pg/mL) 0.5 61.5 94.1 88.2 0.0008◊† 92.6 1145.3 756.1 0.4-11514.8 0.4-1976.7 0.4-2265.6 0.0008◊†
0.7728‡ 0.4488‡
IL-6 (pg/mL) 1.2 1.9 60.0 46.7 0.0008◊† 0.1 45.1 1.1 1.1-80.2 1.1-104.9 1.1-40.2 0.0008◊†
0.4237‡ 0.0059‡
IL-1β (pg/mL) 4.2 3.8 73.3 60.0 0.0008◊† 4.1 174.5 130.6 4.1-152.8 4.1-779.3 4.1-1052.8 0.0008◊†
0.3428‡ 0.8311‡




25.0 n.m. 73.3 53.3 0.1294‡ n.m. 287.7 25.0 n.m. 25.0-1612.0 25.0-646.4 0.0942‡
NE (ng/mL) 0.16 n.m. 100.0 100.0 --- n.m. 0.9 0.8 n.m. 0.27-5.0 0.3-11.4 0.9382‡
◊P-value between controls and CF before therapy (after Bonferroni adjustment), †P-value between controls and CF during therapy (after Bonferroni adjustment),
‡P-value between CF before and during therapy. DL = Detection Limit, n.m. = not measured.
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weight, age and gender and allows the comparison of chil-
dren, adolescents and adults within one study [32,33].Statistical analysis
Experimental data were evaluated with SPSS 19 (IBM,
Ehningen, Germany), MS Excel (Redmont, USA) and
GraphPad Prism 5 (LaJolla, USA). Descriptive statistics
of cytokines were expressed as a median ± range for pa-
tients and healthy controls. Longitudinal values of cyto-
kines were compared using Wilcoxon Test for matched
pairs. Comparison with healthy controls was performed
using the Mann–Whitney U-Test and Fisher’s Exact test.
Correlations between the measured cytokine values and
clinical or serological parameters were calculated using
Spearman’s Rho. Bonferroni Alpha correction was per-
formed for all parameters tested with Spearman, Fisher’s
Exact test and Mann–Whitney U. We tested for seven in-
flammatory markers and total cell count. P-values of these
analyses were multiplied by the number of applied tests.
P-values of < 0.05 were considered statistically significant.Results
Demographic data
The mean age of the 17 CF patients (10 females and
seven males) was 22.7 years (range 7–39, SD 8.2). Nine
patients were homozygous for the CF mutation F508del,
and eight patients were heterozygous. Further class 1–3mutations (394delTT, M1303K, G551D, 2183AA >G)
were found in four patients and class 4–5 mutations
(R347P, 2789 + 5G >A) were also present in four patients.
The median hospitalisation time was 6 days (range 2–14),
and i.v. therapy was continued in most patients as home
treatment for a total of 14 days.
The 52 healthy controls were within the range of 9–60
years old, with a mean age of 31.9 years (SD 13.7; 36
females and 14 males), and were used for a previously
published study [14].
The second sample was gathered within a median of
6 days after beginning i.v. therapy (range 2–14 days). In
the majority of patients, AB therapy was initialised in
hospital and continued at home for a total duration of
14 days. It was directed against P. aeruginosa (in 15/17
patients), S. aureus or S. aureus + H. influenzae (one pa-
tient each) (see Tables 2 and 3 for therapy details). Demo-
graphic and serological data and clinical characteristics of
the included patients are shown in Tables 2 and 3.Serological data
Erythrocyte sedimentation rate (ESR) was elevated in
85% of patients (11/13, range 1 h 1–61 mm/h, 2 h 9–
104 mm/h) and CRP in 41% (7/17, median 5.60 mg/L,
range 2–47 mg/L). IgG was elevated in 35% of patients
(6/17, median 13.30 g/L, range 5.85–19.50 g/L), IgA
(median 1.84 g/L, range 0.07–6.60 g/L) and IgE (median
76.80 KU/L, range 1.90–1944.00 KU/L) in 5/17 patients
Table 2 Clinical and serological characteristics of included patients (nominal variables)
Nominal variables n Absolute frequency
Gender (f/m) 17 10 (53.3%)/7 (47.7%)
Body Mass Index (BMI) scoring*1
17
3 (17.7%)/3 (17.7) /11 (64.7%)/0 (0%)
Severe under-/under-/normal-/overweight
Pancreatic insufficiency 17 13 (76.5%)
Diabetes mellitus 17 6 (35%)




EPOS criteria for CRS at inclusion [28]: No Acute remittent Chronic
Nasal blockage or obstruction or congestion 3 (17.6%) 2 (11.8%) 12 (70.6%)
Anterior or posterior nasal drip 2 (11.8%) 4 (23.5%) 11 (64.7%)
Facial pain or pressure 15 (88.2%) 1 (5.9%) 1 (5.9%)
Reduction or loss of smell 12 (70.6%) 0 4 (23.5%)
Allergic rhinitis 17 7 (41%)
Allergic Bronchopulmonary Aspergillosis (ABPA) 17 2 (11.8%)
History of nasal surgery 17 6 (35%)
Therapy
17
Current azithromycin 13 (77%)
Current steroids nasal 4 (24%)
Recombinant DNase 8 (47%)
i.v. ABs (twice per day, mg/kg):
Ceftazidim (200)/tobramycin (10) 11 (65%)
Tobramycin (10)/meropenem (100) 5 (29%)
Ceftazidim (200)/tobramycin (10)/meropenem (100) 1 (5.9%)
Permanent colonisation LAW with*2: 15 (88%)
P. aeruginosa (mucoid) 17 13 (76.5%)
P. aeruginosa (non-mucoid) 4 (23.5%)
S. aureus 7 (41%)
Permanent/intermittent colonisation UAW with*3: 7 (41.2%)/5 (29.4%)
P. aeruginosa (mucoid) 7 (41.2%)
P. aeruginosa (non-mucoid) 13 (76.5%)
S. aureus 3 (17.7%)/ 4 (23.5%)
P. aeruginosa serum antibody positive:
15
Alcaline protease 3 (20%)
Elastase 6 (40%)
Exotoxine A 4 (27%)
*1: SDSLMS: Standard-Deviation-Score; L = Box cox-power transformation, M =median, S = variation coefficient.
*1: BMI scoring was carried out according to [33].
*2: Permanent and intermittent colonisation was stated using the criteria published by Lee et al. [31], where the authors define a chronic colonisation if more than
50% of cultures within the last year were found to be positive and intermittent if less than 50% of cultures within the last year were found to be positive.
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patients (median 1.23 g/L, range 0.67–2.01 g/L). Fibrino-
gen, as a marker for chronic inflammation, was elevated
in 3/17 patients (21%, median 2.90 g/L, range 2.20–
4.30 g/L).Methodological issues
NL recovery
NL backflow volume did not differ in CF patients prior
to and during therapeutic intervention (median 12.0 mL,
range 8–16 mL and 11.0 mL, range 10–13 mL,
Table 3 Clinical and serological characteristics of included patients (metric and ordinal variables)
Metric and ordinal variables n Mean SD Median Range
Age (yrs.) 17 22.7 8.2 22.0 7-39
Weight (kg) 17 51.7 14.6 51.4 22.0-73.3
Height (cm) 17 160.9 15.57 162 117.8-180
BMI (kg/m2) 17 19.5 3.2 20.4 12.6-24.2
SDSLMS
*1 17 −1.2 1.3 −1.1 −5.5-0.1
ESR after 1/2 h (mm/h) 13 21.2/42.3 18.1/28.7 18/41 1-61/9-104
CRP (mg/l) 17 12.5 13.8 5.6 2.0-47.0
FEV1 (l)/(% predicted) 17 1.9/62.7 0.8/24 1.7/65.5 0.8-3.9/24.3-108.6
MEF75/25 (l)/(% predicted) 15 1.7/46 2.03/39 1.1/30 0.3-7.9/7.4-153.3
Shwachman Score (without chest X-ray) 17 68.2 10.0 70.0 35.0-75.0
Total IgE (KU/l) 17 249.7 481.1 76.8 1.9-1944.0
Total IgG (KU/l) 17 13.8 4.1 13.3 5.9-19.5
Retrieved NL volume prior therapy (mL) 15 11.5 2.0 12.0 8.0-16.0
Retrieved NL volume during/after therapy (mL) 15 11.3 1.19 11.0 10.0-13.0
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the recovery was slightly higher (median, 15.0 mL, range
6–18 mL, P < 0.0001, Figure 1A).Protein concentration
The median NLF protein concentration was 0.25 mg/mL
(range 0.08–0.63 mg/mL) in CF patients prior to therapy
and 0.27 mg/mL (range 0.17–1.33 mg/mL) for CF patients
during therapy. The median NLF protein concentration of
the controls was 0.22 mg/mL (range 0.08–1.70 mg/mL).
Standardisation of analyte concentrations to protein con-
centration did not change the significance levels of the re-


































Figure 1 Differences in NLF recovery volumes (A) and protein concen
during i.v. AB therapy. For NL, each nostril was rinsed with 10 mL of isotCytological analysis
The total cell count was lower in healthy controls (me-
dian 27 cells/mL, range 0–1723 cells/mL) than in un-
treated CF patients (median 108 cells/mL, range 6–744
cells/mL), although the differences did not reach statis-
tical significance (P = 0.088). After 6 days of i.v. AB ther-
apy, the median total cell count decreased to a level
comparable to that in healthy controls (median 28 cells/
mL, range 5–150 cells/mL; P = 0.104, Figure 2A). As
shown in Figure 2B and 2C, some non-significant trends
were seen in the distribution of cell types. Total PMN and
mononuclear cell (MN) counts were lower in healthy con-
trols compared with CF patients before and during i.v. AB

































trations (B) between healthy controls and CF patients, before and
onic saline (total volume: 20 mL).
































































































Figure 2 Differences in NLF total cell counts (A), polymorphonuclear neutrophils (PMN) (B) and mononuclear cells (MN) (C) between
healthy controls and CF patients, before and during i.v. AB therapy.
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and during therapy. Conversely, the proportion of MN
was lower in healthy controls compared with CF.
Comparison of inflammatory markers in healthy controls
and CF patients prior to and during i.v. AB therapy
Detection frequency and concentrations of all measured
inflammatory markers were significantly higher in CF
patients compared with healthy controls (see Table 1).
During AB therapy the median detection frequencies of
IL-8, IL-6, IL-1β and RANTES decreased, while MMP9,
MPO and NE detection frequencies did not change. For
TNF, a slight increase in detection frequency during
treatment was found. When the concentration of inflam-
matory markers was analysed, a decline in all the ana-
lysed parameters except TNF was observed. Notably, a
strong decrease in IL-6 was found in 16/17 CF patients
during AB therapy (P = 0.0059, Table 1 and Figure 3C and
3D) and also in MMP9 and RANTES, where the median
values declined two-fold and 10-fold, respectively (Table 1,
Figure 3A and 3B and Additional file 1: Figure S1).
Correlations between inflammatory markers during i.v.
AB therapy
MMP9 in NL correlated significantly with MPO both
before and during treatment (r = 0.559, P = 0.020, and
r = 0.578, P = 0.013, respectively, data not shown). Before
AB therapy, there was also was a significant positive cor-
relation between MPO and TNF (r = 0.684, P = 0.005).
IL-8 levels in NL before treatment correlated with IL-8
levels during AB therapy in a highly significant manner
(r = 0.719, P = 0.001). Furthermore, IL-8 correlated with
IL-1β, both before and after therapy (r = 0.658, P = 0.008,
and r = 0.646, P = 0.009, respectively). IL-6 correlated
with MMP9 before and during treatment (r = 0.564, P =0.029, and r = 0.630, P = 0.007) and RANTES (r = 0.744,
P = 0.001 and P = 0.001, r = 0.797).
TNF correlated with RANTES both before and during
therapy (r = 0.676, P = 0.006 and, r = 0.870, P = 0.001). Dur-
ing i.v. AB treatment, higher values of TNF were associated
with higher values of IL-1β (r = 0.625, P = 0.013) and with
lower concentrations of NE (r = −0.578, P = 0.031). NE
concentrations in NL before and after therapy showed a
significant correlation within the same patient (r = 0.524,
P = 0.037).
Correlation between inflammatory markers and clinical
parameters
Systemic inflammation evaluated by CRP and ESR, as
well as lung function parameters, was only measured
prior to i.v. treatment. We did not find a significant cor-
relation between systemic inflammation markers (CRP
and ESR) and inflammatory mediators measured in NL.
Moreover, some trends were seen for IL-1β that showed
a negative correlation to CRP.
At the starting point of the longitudinal study we found
no significant correlations between FEV1 (% predicted)
and cytokine concentrations, except for MMP9 and IL-1β,
which revealed a trend for a positive correlation.
Discussion
The present study describes, for the first time, changes
in cytokine expression and cytological dynamics in the
NLF of CF patients during i.v. AB intervention.
We have demonstrated that the total cell count in NL,
which was significantly increased in CF patients com-
pared with healthy controls, declined to normal levels
during a median time of 6 days of systemic AB treat-
ment. This corresponds well with findings from the





















































































































Figure 3 Differences in inflammatory markers in healthy controls and CF patients, before and during i.v. antibiotic therapy.
Matrixmetalloproteinase 9 (MMP9) was clearly attenuated during therapy (A). RANTES levels declined under AB treatment (B). IL-6 was found to
be significantly elevated in CF (C), declining during antibiotic treatment in almost all CF patients (D).
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are lower in healthy controls compared with CF patients.
Indeed, the percentages of PMN vs. MN were slightly
different, but not significantly so, between CF patients
and healthy controls and no change in the percentage
was observed during AB treatment. This may support
the results of Johansen et al. [35], who found a reduced
PMN response, but elevated non-inflammatory secretory
IgA levels, on P. aeruginosa biofilms colonising CF pa-
tients’ upper airways. Furthermore, the level of IgA can
discriminate between non-, intermittent and chronically
colonised patients with the high concentration of IgA in
the last group being used as a diagnostic tool [36]. On this
basis, the authors hypothesise that impaired sinonasal
PMN recruitment gives rise to a failure to eradicate P. aer-
uginosa from the upper airway segment by the immune
system. Moreover, histological studies have revealed an
enhanced presence of mast and plasma cells in sinonasal
tissue from CF patients [37]. Our results also correspond
to those from sputum [38], where AB treatment had no
influence on total or differential cell count in CF lowerairway secretions, which is in contrast to the expected re-
duction of inflammation with therapeutic reduction of
pathogens.
The inflammatory markers MPO, IL-8, IL-6 and IL-1β
were found significantly more often in NLF of CF pa-
tients, when compared with healthy controls. This is in
line with previous findings from retrospective studies
[14]. In addition to the aforementioned cytokines, TNF
concentration in the upper airway lavage was found to
be higher in CF patients compared with controls. For
LAW sampling by BAL, Elizur et al. [39] reported simi-
lar results. Furthermore, the median expression levels of
MPO, IL-8, IL-6, and IL-1β in NLF were significantly
higher in our CF cohort compared with healthy controls.
During i.v. therapy detection the frequency of IL-8,
IL-6, IL-1β and RANTES decreased. Simultaneously,
IL-6 levels in NLF declined significantly. RANTES and
MMP9 decreased to a lower, but not significant, extent.
Notably, the changes of IL-6 in NL are in accordance
with the recent publication of Paats et al. [40]. In this
study, UAW inflammation in CF patients was assessed
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tion. In contrast, our study focused on the change of UAW
inflammation after only 6 days of elective IV antibiotic
treatments. In this regard, the results from Paats et al. and
our study underline that IL-6 is a highly sensitive bio-
marker for infection and antibiotic effects in non-invasively
sampled airway secretions from the upper airways.
Additionally, no changes in the expression levels of
NE, which was detected for the first time in NLF, were
observed during the applied therapeutic intervention.
Also TNF, MPO, IL-8 and IL-1β remained unchanged
during 6 days of therapy. We cannot differentiate whether
this is due to the relatively short period of systemic AB
treatment or the above-mentioned reduced PMN re-
sponse in the upper airways, as suggested by Johansen
et al. who hypothesised the presence of different defence
mechanisms in the upper and lower airways [35]. This is
in line with data from our recent study, where higher neu-
trophil counts and IL-8 levels were detected in sputum
compared with nasal lavage fluid [41]. Moreover, the hy-
pothesis of differences in host defence mechanisms be-
tween the upper and lower airways was also supported by
data from a current work from Michl et al. Nasally ex-
haled nitric oxygen (NO), which is a first-line defence
mechanism in paranasal sinuses, was significantly reduced
in CF patients with elevated CRP and ESR, an effect not
seen in the LAW [42].
Interestingly, there is a strong correlation between dif-
ferent inflammatory markers. MMP9 levels were associ-
ated with MPO and IL-6 levels both prior to and during
therapy. Furthermore, RANTES levels are associated
with TNF and a positive correlation was found to exist
between IL-1β and IL-8 prior to and during therapy. We
analysed protein-protein interactions in-silico, using the
online databank string-db.org (http://string-db.org/). Add-
itionally, other publications have shown a correlation be-
tween MPO and MMP9 [43], but we did not find a direct
interaction between them. It is postulated that MPO acti-
vates MMP9, which is released in an inactive form [44].
As MPO plays an important role during oxidative bursts,
a correlation with other pro-inflammatory markers may
be due to increased Reactive Oxygen Species (ROS). Ex-
pression of MMP9 is induced by IL-1β, IL-6 or TNF
[45,46], and IL-1β increases IL-6 expression [47]. IL-1β is
degraded by MMPs, a process that can be blocked by
TIMP-1 [48]. For IL-6 and RANTES no direct interac-
tions were listed, but both markers are elevated in tissues
infected with P. aeruginosa [49] and during acute pulmon-
ary exacerbation in CF patients [50]. An interaction be-
tween IL-1β and IL-8 has been described previously: IL-1β
stimulates IL-8 expression [51], and binds and activates
IL-8. ROS stimulates the release of IL-1β and TNF, which
leads to enhanced detachment of IL-8, IL-6, MMP9 and
TNF (e.g. via NFκB or Mitogen-Activated-Protein-Kinase(MAPK)) [52]. Bacterial infections lead to NFκB activation
via Toll-like receptors in airway epithelial cells and alveo-
lar macrophages or dendritic cells, which in turn induce
transcription of pro-inflammatory cytokines such as IL-6
and IL8. Furthermore cytokines, such as IL-1β and TNF,
can activate NFκB, which seems to be a key factor in NLF
inflammation signalling. NFκB is inhibited by macrolide
AB-like azithromycin (AZM). Seventy per cent of our pa-
tients received AZM as anti-inflammatory therapy. In
these patients we found lower IL-1β levels when com-
pared with untreated patients (Additional file 1: Figure
S2), but because of the small proportion of untreated pa-
tients, the observed differences may not be representative.
Therefore, in future studies, it would be of great interest
to evaluate the NFκB levels and activity in airway epithelial
cells.
The present study did not reveal significant correla-
tions between systemic inflammation and inflammatory
marker concentrations in NL, which accords well with
the hypothesis of a compartmentalised infection and in-
flammation in CF. Moreover, we found no correlation
between lung function and CRS status. This may be due
to the small size of the study cohort. As a result of the
short period of time and the wide range of duration that
patients stayed in the hospital after the initialisation of i.v.
therapy, we did not collect systemic inflammatory markers
and lung function data during therapy. The heterogeneity
of the investigated patients regarding age, pulmonary
function and nutritional status is compensated for by the
longitudinal nature of the study, as assessing changes in
nasal inflammatory markers during intravenous AB treat-
ment was its principal aim. Therefore, future studies
should assess larger patient cohorts for longer periods and
include NL and LAW assessment at the end of therapy,
and if possible, assessment of systemic inflammatory
markers and microbiology.
NL may be of interest for other systemic and topical
therapeutic approaches in CF, and also other respiratory
diseases including allergic rhinitis/allergic asthma and im-
mune deficiencies. Moreover, microbiological and inflam-
matory marker assessment of NLF can provide information
about the prevalence and impact of compartmentalised air-
way infection in various respiratory diseases, for example
ventilator-associated pneumonia and sepsis.
Conclusions
In contrast to BAL, nasal lavage is a non-invasive method
and allows for the frequent sampling of airway surface li-
quid. In the present study, we found substantial differ-
ences in longitudinally collected NLF from CF patients,
both before and after a median of 6 days of i.v. AB treat-
ment, and compared with healthy individuals. Substantial
differences between the three groups were evident after
only this short period of therapy. Total NL cell counts,
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controls. IL-6 was significantly reduced, with a trend to-
wards reduced RANTES and MMP9. The latter, together
with NE, were assessed in the NL of CF patients for the
first time. Our findings highlight the use of NL as a poten-
tial tool for clinical and scientific studies.
Additional file
Additional file 1: Figure S1. Differences in inflammatory markers in
healthy controls and CF patients, before and during i.v. antibiotic therapy.
Significant differences in myeloperoxidase between CF and healthy
controls were observed and a slight decline under AB intervention was
found (S1A). IL-1β (S1B) and IL-8 (S1C) levels were significantly lower in
controls than in CF patients. TNF was significantly elevated in CF patients
(S1D), but there was no change during AB treatment. No changes in NE
were observed under AB treatment (S1E). Figure S2. Lower IL-1β levels
were observed in AZM-treated patients (median 140.6 ng/mL, range
4.1–467.2) compared with untreated patients (747.1 ng/mL, range
219.5–779.3, P = 0.0348).
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